Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Country of Publication: England NLM ID: 8704308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2710 (Electronic) Linking ISSN: 02694727 NLM ISO Abbreviation: J Clin Pharm Ther Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Wiley-Blackwell Pub.
      Original Publication: Oxford : Blackwell Scientific Publications, c1987-
    • Subject Terms:
      Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use ; Hypercholesterolemia/*drug therapy ; Hypercholesterolemia/*genetics ; Lipids/*blood ; Liver-Specific Organic Anion Transporter 1/*genetics ; Polymorphism, Single Nucleotide/*genetics ; Simvastatin/*therapeutic use; Adult ; Aged ; Aged, 80 and over ; Alleles ; Biomarkers/blood ; Female ; Gene Frequency/genetics ; Humans ; Hypercholesterolemia/blood ; Male ; Middle Aged ; Thailand
    • Abstract:
      What Is Known: SLCO1B1 polymorphisms have been reported to affect the responses to statin therapy. However, the association of these polymorphisms and lipid-lowering responses has been inconsistent.
      Objective: To investigate the effect of SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms on the lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
      Methods: Three hundred and 91 hypercholesterolaemic patients in Southern Thailand were enrolled and treated with simvastatin 20 or 40 mg per day. Among them, 191 and 200 patients were treated for 3 and 12 months, respectively. Serum lipids were measured before and after the treatment. SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms were analysed using polymerase chain reaction-high-resolution melting (PCR-HRM).
      Results: The allele frequencies of the SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms in Thai hypercholesterolaemic patients were 74.9%, 11.8% and 37.2%, respectively. After treatment with 20-40 mg simvastatin daily for 3 and 12 months, TC, TG and LDL-C concentrations were significantly lower than at baseline (P < .05). However, there was no a significant change in serum HDL-C after simvastatin treatment for 3 and 12 months (P > .05). Moreover, there was no association between SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms and lipid-lowering response to 3 and 12 months of either 20 or 40 mg/day simvastatin treatment.
      What Is New and Conclusion: SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms may not be useful as genetic markers of lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
      (© 2018 John Wiley & Sons Ltd.)
    • Grant Information:
      Walailak University fund; No. WU57211 Institute of Research and Development
    • Contributed Indexing:
      Keywords: SLCO1B1; hypercholesterolaemia; polymorphisms; response; simvastatin
    • Accession Number:
      0 (Biomarkers)
      0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
      0 (Lipids)
      0 (Liver-Specific Organic Anion Transporter 1)
      0 (SLCO1B1 protein, human)
      AGG2FN16EV (Simvastatin)
    • Publication Date:
      Date Created: 20180326 Date Completed: 20181212 Latest Revision: 20220321
    • Publication Date:
      20240829
    • Accession Number:
      10.1111/jcpt.12682
    • Accession Number:
      29575099